ANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of “Buy” by Brokerages

ANI Pharmaceuticals Inc (NASDAQ:ANIP) has earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $73.25.

A number of brokerages recently issued reports on ANIP. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price objective on the stock in a report on Thursday. Raymond James set a $73.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 28th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Finally, ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th.

Shares of ANIP stock traded up $2.78 on Tuesday, hitting $70.54. 230,232 shares of the stock were exchanged, compared to its average volume of 81,295. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.68 and a current ratio of 0.92. The company has a market capitalization of $835.97 million, a price-to-earnings ratio of 15.30 and a beta of 2.41. ANI Pharmaceuticals has a one year low of $36.92 and a one year high of $72.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.08. The business had revenue of $57.12 million for the quarter, compared to analysts’ expectations of $53.48 million. ANI Pharmaceuticals had a return on equity of 28.84% and a net margin of 7.69%. The firm’s quarterly revenue was up 20.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.08 EPS. Equities analysts predict that ANI Pharmaceuticals will post 5.97 EPS for the current year.

In other ANI Pharmaceuticals news, SVP Robert W. Schrepfer sold 4,651 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $64.43, for a total value of $299,663.93. Following the sale, the senior vice president now owns 53,484 shares of the company’s stock, valued at approximately $3,445,974.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Arthur Przybyl sold 27,625 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25. The disclosure for this sale can be found here. Corporate insiders own 33.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ANIP. First Trust Advisors LP purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $710,000. Teachers Retirement System of The State of Kentucky raised its holdings in shares of ANI Pharmaceuticals by 99.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,000 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at about $1,052,000. Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals by 6.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 511,881 shares of the specialty pharmaceutical company’s stock valued at $28,941,000 after buying an additional 32,556 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of ANI Pharmaceuticals by 2.9% during the 3rd quarter. Renaissance Technologies LLC now owns 178,400 shares of the specialty pharmaceutical company’s stock valued at $10,087,000 after buying an additional 5,100 shares in the last quarter. 59.75% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Story: Stop Order Uses For Individual Investors

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.